Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy

Ikram A. Burney, Ross J. Maxwell*, Stan B. Field, Cheryl L. McCoy, John R. Griffiths

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

A selective reduction in tumour blood flow (TBF) could enhance the effects of hyperthermia treatment and of drugs toxic to hypoxic cells. Vasodilator-induced changes in TBF were monitored in transplanted rat fibrosarcomas by non-invasively measuring the uptake of D2O using 2H nuclear magnetic resonance spectroscopy. Hydralazine (1 or 5 mg kg-1) caused a large (45% reduction in mean arterial blood pressure (MABP) and a 40-60% reduction in TBF. Low-dose hydralazine (0.1 mg kg-1) caused a 20% reduction in MABP but no significant change in TBF. The doses of prazosin (1 mg kg-1) and calcitonin-gene related peptide (CGRP, 1 nmol kg-1) which caused a 20% reduction in MABP led to a 50-60% reduction in TBF. These results demonstrate the advantage of prazosin and CGRP over hydralazine for the reduction of TBF despite a small hypotensive effect. CGRP may be the most suitable of these agents for clinical use because of its short physiological half-life.

Original languageEnglish
Pages (from-to)367-371
Number of pages5
JournalActa Oncologica
Volume34
Issue number3
DOIs
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Fingerprint Dive into the research topics of 'Effect of vasoactive drugs on tumour blood flow as determined by <sup>2</sup>h nuclear magnetic resonance spectroscopy'. Together they form a unique fingerprint.

Cite this